What Does Independent Science Say About VigRX? A Peer-Reviewed Study Says Quite a Lot.

Most men have seen the headlines before. A supplement makes a big claim, the science is thin, and nobody checks the label. So when VigRX was put in front of independent researchers at three separate institutions, the question on the table was not what the brand wanted to say about itself. The question was what the science actually showed.

The answer, published in a peer-reviewed journal in 2010, was rigorous and specific.

Researchers at AIBMR Life Sciences, Natural Remedies Private Limited in Bangalore, Flora Research Laboratories in Oregon, General Standard Laboratory in Taiwan, and Mae Fah Luang University in Thailand conducted five separate investigations on VigRX. The studies examined the formula for purity, its mechanism of action, and its effects on sexual behavior, erectile function, and sperm quality in a validated animal model.

None of the researchers had a financial interest in the product.

Before anything else, the researchers tested VigRX for pharmaceutical adulterants. This is not a minor issue. The FDA has repeatedly flagged men's sexual health supplements for hidden additions of sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and their analogues. These hidden ingredients can cause dangerous interactions, especially for men on nitrates.

Two separate analytical tests screened VigRX against 16 known PDE-5 inhibitor analogues and 180 active pharmaceutical ingredients across 19 drug categories, including steroids, CNS stimulants, hormones, narcotics, and cardiovascular drugs.

Result: VigRX was found to be completely free of all tested pharmaceutical adulterants. No detectable levels. Clean.

This matters for two reasons. First, it means any measured effects in the following studies were from the botanical formula itself, not from hidden pharmaceutical contamination. Second, it means men taking VigRX were not being unknowingly exposed to prescription-strength compounds without their consent.

Researchers also tested VigRX in a Rho-kinase II enzyme inhibition assay. The Rho-kinase pathway plays a direct role in penile erection. When Rho-kinase is active, it keeps smooth muscle contracted, which restricts blood flow. When it is inhibited, smooth muscle relaxes, blood flow increases, and erection quality improves.

VigRX demonstrated concentration-dependent inhibitory effects on the Rho-kinase II enzyme, with an IC50 of 1673.18 micrograms per milliliter. The researchers noted this suggests Rho-kinase inhibition is likely one contributing mechanism, alongside other possible actions including effects on the nitric oxide pathway.

In plain terms: the botanical formula produced measurable biological activity at the same enzyme that erectile function depends on.

In the 14-day study using Sprague-Dawley rats, male subjects treated with VigRX at 30 mg/kg/day showed statistically significant improvements across every measured parameter of sexual behavior compared to the untreated control group (p < 0.05).

Ejaculation latency was significantly reduced. Mounting frequency, intromission frequency, and ejaculation frequency all increased. Erect penile length and width both increased. Intracavernosal pressure increased significantly (p < 0.001 at the higher dose). Sperm concentration also increased at the higher dose.

Body weight and organ weights, including the penis, testes, prostate, seminal vesicles, and adrenal glands, were unchanged. Histopathological examination of all tissues showed no abnormalities.

The 12-week study using the lower dose (15 mg/kg/day) continued to show increases in intracavernosal pressure, sperm concentration, and erect penile width, all statistically significant versus controls.

At the conclusion of 12 weeks, VigRX-treated animals showed a statistically significant increase in serum testosterone levels compared to controls (p < 0.05). Mean testosterone in the treated group was 6.20 ng/mL versus 3.66 ng/mL in controls.

No histopathological abnormalities were found in any organs. Blood chemistry parameters, including liver enzymes, kidney markers, and lipid profiles, were all within normal ranges.

Across both studies: consistent improvements in intracavernosal pressure, sperm concentration, and erect penile dimensions. No organ toxicity. No histopathological changes.

The authors concluded that these results provide scientific evidence in support of the purity, safety, and potential efficacy of VigRX in supporting male sexual health. They identified Rho-kinase inhibition and increased serum testosterone as two likely mechanisms of action, and called for further human clinical trials.

The research was published in The Open Natural Products Journal, Volume 3, 2010.

Smitasiri Y, D'Souza P, Neal-Kababick J, Schauss AG. An Initial Evaluation of the Safety, Efficacy and Purity of VigRX, a Herbal Combination Formula, for the Enhancement of Male Sexual Health. The Open Natural Products Journal, 2010, 3, 10-19.

Click here to read the full report →
Explore the complete VigRX product line →